Keyword Search Results for "dyslipidemia"

Scirica, B. M., Cannon, C. P. Treatment of elevated cholesterol Circulation. 2005;111(21):e360-3.

Cannon, C. P. Combination therapy in the management of mixed dyslipidaemia J Intern Med. 2008;263(4):353-65. Abstract

Shiffman, D., Sabatine, M. S., Louie, J. Z., Kirchgessner, T. G., Iakoubova, O. A., Campos, H., Devlin, J. J., Sacks, F. M. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial Am J Cardiol. 2010;105(9):1300-5. Abstract

Li, Y., Sabatine, M. S., Tong, C. H., Ford, I., Kirchgessner, T. G., Packard, C. J., Robertson, M., Rowland, C. M., Bare, L. A., Shepherd, J., Devlin, J. J., Iakoubova, O. A. Genetic variants in the KIF6 region and coronary event reduction from statin therapy Hum Genet. 2011;129(1):17-23. Abstract

Preiss, D., Seshasai, S. R., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., DeMicco, D. A., Barter, P., Cannon, C. P., Sabatine, M. S., Braunwald, E., Kastelein, J. J., de Lemos, J. A., Blazing, M. A., Pedersen, T. R., Tikkanen, M. J., Sattar, N., Ray, K. K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA. 2011;305(24):2556-64. Abstract

Wiviott, S. D. ILLUMINATE sheds more light Circulation. 2011;124(5):536-7.

Desai, Nihar R., Kohli, Payal, Giugliano, Robert P., Kim, Jae B., Mohanavelu, Satishkumar, Hoffman, Elaine, Liu, Thomas, Scott, Robert, Wasserman, Scott, Sabatine, Marc S. AMG 145, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), Facilitates Achievement of NCEP LDL-Cholesterol Goals in High-Risk Patients Circulation. 2012;126(23):2791-2791.

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017. Abstract

Giugliano, Robert P., Desai, Nihar R., Kohli, Payal, Somaratne, Ransi, Huang, Fannie, Mohanavelu, Satishkumar, McDonald, Shannon T., Abrahamsen, Timothy E., Wasserman, Scott M., Scott, Robert, Sabatine, Marc S. LAPLACE-TIMI 57 Primary Results Circulation. 2012;126(23):2790-2791.

Kohli, P., Cannon, C. P. Triglycerides: how much credit do they deserve? Med Clin North Am. 2012;96(1):39-55. Abstract

Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R., Huang, F., Knusel, B., McDonald, S., Abrahamsen, T., Wasserman, S. M., Scott, R., Sabatine, M. S. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy Clin Cardiol. 2012;35(7):385-91. Abstract

Kohli, Payal, Desai, Nihar R, Giugliano, Robert P, O'Donoghue, Michelle L, Somaratne, Ransi, Hoffman, Elaine B, Huang, Fannie, Wasserman, Scott M, Scott, Robert, Sabatine, Marc S Abstract 17630: Reduction in Lipoprotein (a) with the PCSK9 Inhibitor AMG145 in Hypercholesterolemic Patients on Background Statin: Results from the LAPLACE-TIMI 57 Trial Circulation. 2012;126(21 Supplement):A17630. Abstract

Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Jr., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., Dansky, H. M. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib J Lipid Res. 2013;54(2):467-72. Abstract

Desai, N. R., Giugliano, R. P., Zhou, J., Kohli, P., Somaratne, R., Hoffman, E., Liu, T., Scott, R., Wasserman, S. M., Sabatine, M. S. AMG 145, A Monoclonal Antibody Against PCSK9, Facilitates Achievement of NCEP-ATP III LDL-C Goals Among High Risk Patients: An Analysis From the LAPLACE-TIMI 57 Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Desai, N. R., Kohli, P., Giugliano, R. P., O'Donoghue, M. L., Somaratne, R., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., Scott, R., Sabatine, M. S. AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation. 2013;128(9):962-9. Abstract

Hochholzer, W., Giugliano, R. P. Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD? Curr Atheroscler Rep. 2013;15(1):290. Abstract

Koren, M. J., Giugliano, R. P., Raal, F. J., Sullivan, D., Bolognese, M., Langslet, G., Civeira, F., Somaratne, R., Nelson, P., Liu, T., Scott, R., Wasserman, S. M., Sabatine, M. S., for the, Osler Investigators Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial Circulation. 2013;NA(NA):NA. Abstract

Martin, S. S., Blaha, M. J., Toth, P. P., Joshi, P. H., McEvoy, J. W., Ahmed, H. M., Elshazly, M. B., Swiger, K. J., Michos, E. D., Kwiterovich, P. O., Kulkarni, K. R., Chimera, J., Cannon, C. P., Blumenthal, R. S., Jones, S. R. Very Large Database of Lipids: Rationale and Design Clin Cardiol. 2013;NA(NA):NA. Abstract

Messe, S. R., Pervez, M. A., Smith, E. E., Siddique, K. A., Hellkamp, A. S., Saver, J. L., Bhatt, D. L., Fonarow, G. C., Peterson, E. D., Schwamm, L. H. Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke Stroke. 2013;44(5):1354-9. Abstract

Steen, D. L., Bhatt, D. L. Statin potency associated with incident diabetes in a real-world evaluation Evid Based Med. 2013;NA(NA):NA.

Gotto, A. M., Jr., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P. Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., for the, Proficio Investigators Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J. 2014;NA(NA):NA. Abstract